Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Emerges from Bankruptcy Protection

NEW YORK (GenomeWeb News) - Vermillion today said that it has emerged from US Bankruptcy Protection less than 10 months after filing for Chapter 11.

The Fremont, Calif.-based molecular diagnostics firm said that all of its creditors have received 100 percent of allowed claims. It also said that its common stock has been fully restated.

"Vermillion is emerging from bankruptcy as a well-capitalized, leading diagnostics company, poised to launch our OVA1 test," Gail Page, executive chair of Vermillion, said in a statement. "We are in a position to resume development of our other programs in ovarian cancer and peripheral arterial disease."

Vermillion had filed for Chapter 11 bankruptcy protection on March 30, 2009, but stayed in business as it sought US Food and Drug Administration clearance for the OVA1 test, which the firm received in September.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.